When the APC gene is mutated, cells lose a critical brake on growth signaling, allowing them to divide uncontrollably. This is the initiating event in most colorectal cancers. About 70% of all sporadic (non-inherited) colorectal cancers carry a mutation in APC, and people who inherit a defective copy from a parent face a near-certain lifetime risk of developing hundreds to thousands of precancerous polyps in the colon.
How the APC Protein Normally Works
The APC protein acts as a scaffold inside a molecular machine called the beta-catenin destruction complex. Beta-catenin is a signaling molecule that, when it accumulates in a cell, travels to the nucleus and switches on genes that promote cell growth and division. In healthy cells, the destruction complex (made up of APC and several partner proteins) continuously captures beta-catenin, tags it with chemical markers, and sends it to be broken down. This keeps beta-catenin levels low and prevents cells from growing when they shouldn’t be.
When a Wnt signal arrives from neighboring cells, the destruction complex temporarily shuts down, beta-catenin rises, and growth genes activate. This is normal and essential during development and tissue repair. The problem starts when APC is mutated: the destruction complex can’t do its job even in the absence of a Wnt signal. Beta-catenin accumulates permanently, growth genes stay switched on around the clock, and the cell begins behaving as though it’s constantly receiving a “grow” command.
Where Mutations Tend to Occur
Most cancer-causing APC mutations are “truncating,” meaning they cut the protein short so it can’t function. These mutations cluster in a specific stretch of the gene, roughly between codons 1250 and 1450 in colorectal tumors. In upper gastrointestinal tumors (stomach and small intestine), the hotspot shifts slightly, clustering between codons 1400 and 1580, with about 74% of mutations falling in that range. These regions overlap with the parts of the protein responsible for binding and destroying beta-catenin, which is why mutations here are so damaging.
Familial Adenomatous Polyposis
People who inherit one defective copy of the APC gene from a parent develop a condition called familial adenomatous polyposis, or FAP. Because every cell in their body already carries one bad copy, it takes only a single additional mutation in the remaining copy for a colon cell to lose APC function entirely. This happens frequently, and the result is dramatic: polyps begin appearing in the colon at an average age of 16, eventually numbering in the hundreds or thousands. Classic FAP is defined by the presence of at least 100 adenomatous polyps. A milder form, called attenuated FAP, involves 20 or more polyps with a later onset.
Without intervention, these polyps will almost inevitably progress to colorectal cancer, typically by the 40s. This is why surveillance and preventive surgery are central to managing the condition.
Effects Beyond the Colon
APC mutations don’t just affect the colon. The gene is active throughout the body, and inherited mutations can cause a range of problems historically grouped under the name Gardner syndrome. These include:
- Desmoid tumors: firm, fibrous growths that develop in about 20% of FAP patients, most often in the abdomen around age 30. These are a significant cause of illness and death in FAP, even though they aren’t cancerous in the traditional sense, because they can compress organs and blood vessels.
- Osteomas: benign bone growths, most commonly on the skull and jaw, occurring in roughly 20% of patients compared to 1-2% of the general population.
- Dental abnormalities: present in about 17% of patients, including extra teeth, cysts, and delayed tooth development in children.
- Duodenal polyps and cancer: polyps develop in the upper small intestine in about 65% of FAP patients, with a lifetime risk of duodenal cancer around 12%.
- Other cancers: thyroid cancer, pancreatic cancer, liver tumors (hepatoblastoma, especially in children), and adrenal gland tumors all occur at elevated rates.
APC mutations are also linked to a specific type of brain tumor called medulloblastoma. This association, sometimes referred to as Turcot syndrome type 2, involves patients with FAP who develop brain tumors, most commonly medulloblastoma. Rarer cases include pituitary tumors, ependymomas, and astrocytomas.
APC Mutations in Non-Inherited Colorectal Cancer
You don’t need to inherit a faulty APC gene to be affected by APC mutations. In a comprehensive analysis of 630 sporadic colorectal cancers (cancers that arose without a family syndrome), nearly 70% carried truncating APC mutations, and about 75% showed at least one significant hit to the gene when combining mutations with loss of the other copy. Roughly half of all tumors had two separate hits to APC, effectively knocking out both copies. Only about 25% of sporadic colorectal cancers showed no detectable APC damage at all, underscoring how central this gene is to the disease.
Interestingly, APC mutation status may carry some prognostic information. In non-metastatic colorectal cancer (stages I through III), patients whose tumors carried APC mutations had better overall survival and lower recurrence rates than those with intact APC. In stage III disease specifically, the overall survival rate was 94.4% for APC-mutated tumors compared to 67.7% for tumors without APC mutations. This seems counterintuitive, but tumors without APC mutations tended to be more poorly differentiated and showed higher activity of other aggressive growth pathways, suggesting they had found alternative, potentially more dangerous routes to becoming cancerous.
Screening for APC Mutation Carriers
For people who carry a known APC mutation, colonoscopy screening begins remarkably early. U.S. guidelines recommend starting between ages 10 and 15, with repeat exams every one to two years depending on how aggressively polyps are developing. European guidelines are similar, starting at 12 to 14 with exams every one to three years. Upper gastrointestinal screening (looking at the stomach and small intestine) begins between ages 20 and 25.
Screening intervals tighten if certain risk factors are present: a mutation at codon 1309 (associated with particularly severe disease), 100 or more polyps at colonoscopy, any polyp larger than 10 millimeters, symptoms, or rapid polyp progression. For patients with symptomatic disease or a confirmed severe mutation, screening should begin immediately regardless of age.
Surgical Prevention
Because polyps in classic FAP are too numerous to remove individually, preventive surgery is the standard approach. The timing and type of surgery depend on polyp burden and location.
The least invasive option removes the colon but preserves the rectum, reconnecting the small intestine directly. This avoids an ostomy bag and maintains relatively normal bowel function, but requires ongoing surveillance of the remaining rectum because polyps can still develop there. When rectal disease is severe or when polyps recur aggressively, the rectum is removed as well, and the surgeon creates an internal pouch from the small intestine that connects to the anus. This eliminates almost all at-risk tissue while still allowing the patient to pass stool normally. In cases where that pouch fails or develops severe polyps of its own, a permanent ostomy (an external bag) becomes necessary.
The goal in every case is to remove tissue before cancer develops. With appropriate surveillance and timely surgery, most people with FAP can avoid colorectal cancer entirely, though they require lifelong monitoring for the many other manifestations of APC dysfunction throughout the body.